MedTrace Logo

Function of Platelets Used for Transfusions

NCT05038722 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2023-07-13

No results posted yet for this study

Summary

Cytotoxic treatment for malignant hematologic disorders often casue thrombocytopenia that can result in life threatening bleedings. This is prevented by platelet transfusions but these can cause serious transfusion reactions and thus the number of transused platelet concentrates should be limited. It is therefore important that the platelet concentrates contain functional platelets with long circulation time in the bloodstream.

We have developed a method with flow cytometry to measure platelet function markers. It allows us to determine which pathways that are initiated upon activation.

The aim of this project is to assess to what degree spontaneous activation of platelets as well as their activation capacity affects the transfusion response (i.e. uptake in the circulation and circulation time) in the recipient.

The hypothesis is that transfusion of platelets with low spontaneous activation and high activation capacity will lead to a higher transfusion response in the recipient.

Conditions

Interventions

OTHER

Platelet transfusion

Transfusion of platelet concentrates according to routine practice.

Sponsors & Collaborators

  • Sofia Ramström

    lead OTHER

Principal Investigators

  • Sofia Ramström, Ass. Prof · Örebro University, Sweden

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-22
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05038722 on ClinicalTrials.gov